Merck, 208921-1MG, Calmodulin Kinase IINtide, Myristoylated

General description
The myristoylated form of CaMK IINtide (Cat. No. 208920), a potent, specific inhibitor of Ca²⁺/Calmodulin kinase II (CaMK II) (IC₅₀ = 50 nM for total and Ca²⁺-independent CaMK II activity). The peptide sequence corresponds to the inhibitory domain of the CaMK II inhibitory protein, CaMK IIN. Exhibits inhibitory activity across converged species, including rat brain, goldfish brain, and Drosophila (IC₅₀ = 100-400 nM). Shown to completely inhibit the phosphorylation of GluR1 fusion protein at a concentration of 1 µM. Does not inhibit CaMK I, CaMK IV, CaMKK, PKA, or PKC. The peptide has been modified at the amino terminal lysine with the addition of three glycine residues and myristoylated to improve cell-permeability.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
Calmodulin-Dependent Protein Kinase (CaM Kinase)-2
Product does not compete with ATP.
Reversible: no
Target IC₅₀: 50 nM against cam Kinase-2
Packaging
Packaged under inert gas
Physical form
Supplied as a trifluoroacetate salt.
Preparation Note
Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at-20°C.
Other Notes
Myr-N-Gly-Gly-Gly-Lys-Arg-Pro-Pro-Lys-Leu-Gly-Gln-Ile-Gly-Arg-Ala-Lys-Arg-Val-Val-Ile-Glu-Asp-Asp-Arg-Ile-Asp-Asp-Val-Leu-Lys-OH
Sodering, T.R., et al. 2001. J. Biol. Chem.276, 3719.
Chang, B.H., et al. 1998. Proc. Natl. Acad. Sci. USA95, 10890.
Pereda, A.E., et al. 1998. Proc. Natl. Acad. Sci. USA95, 13272.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)